ATOSSA THERAPEUTICS, INC. ATOS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-11.97
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$34.8M | — | -$29.8M | $39.4M |
| 2024 | — | -$25.5M | — | -$21.0M | $71.5M |
| 2023 | — | -$30.1M | — | -$21.0M | $91.0M |
| 2022 | — | -$27.0M | — | -$20.8M | $118.0M |
| 2021 | — | -$20.6M | — | -$16.5M | $138.1M |
| 2020 | — | -$17.8M | — | -$11.6M | $27.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Steinhart Richard I | director | 2026-05-12 | Grant | 10,000 | — |
| Chen Shu-Chih | director | 2026-05-12 | Grant | 10,000 | — |
| Remmel H. Lawrence | director | 2026-05-12 | Grant | 10,000 | — |
| Finn Jonathan | director | 2026-05-12 | Grant | 10,000 | — |
| Galli Stephen J | director | 2026-05-12 | Grant | 10,000 | — |
| Cigler Tessa | director | 2026-05-12 | Grant | 10,000 | — |
| QUAY STEVEN C | President & CEO | 2026-03-27 | Grant | 65,000 | — |
| Daniel Mark James | Chief Financial Officer | 2026-03-26 | Grant | 63,000 | — |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.97 (distress)
- Working capital / assets 0.785
- Retained earnings / assets -5.179
- EBIT / assets -0.78
- Equity / liabilities 4.767
Source: SEC EDGAR filings · CIK 0001488039 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.